Hormonal
Letrozole is the first-line pharmacological treatment for anovulatory infertility in women with PCOS, offering higher live birth and clinical pregnancy rates compared to Clomiphene Citrate (CC).
If you have PCOS and are struggling with infertility due to lack of ovulation, Letrozole is now the preferred first medication. It works better than the older drug Clomiphene (CC) and has a lower risk of twins and complications. It is often used off-label, so discuss this with your doctor.
Letrozole is considered first-line treatment for women with PCOS and anovulatory infertility. Letrozole followed by timed intercourse improves live birth rate and clinical pregnancy rates compared with CC with no difference in rates of ovarian hyperstimulation syndrome (OHSS) and reduced multiple pregnancy.
Why this rating
Based on comparative studies showing superiority over CC.
Source
A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines
Adriana C. H. Neven et al. · Seminars in Reproductive Medicine · 2018
DOI 10.1055/s-0038-1668085
More from this paper
- Lifestyle interventions including healthy diet, physical activity, and behavioral strategies are the first-line treatment for PCOS, improving metabolic, reproductive, and psychosocial outcomes.Good
- Combined oral contraceptive pills (COCPs) are recommended as first-line medical treatment for managing hyperandrogenism and regulating menstrual cycles in PCOS.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →